Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Non-medical switching: save today and pay tomorrow.

Benucci M, Cantini F.

J Med Econ. 2019 Nov;22(11):1160-1161. doi: 10.1080/13696998.2019.1651132. Epub 2019 Sep 9. No abstract available.

PMID:
31364882
2.

Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study.

Nannini C, Niccoli L, Sestini S, Laghai I, Coppola A, Cantini F.

Ann Rheum Dis. 2019 Oct;78(10):1444-1446. doi: 10.1136/annrheumdis-2019-215585. Epub 2019 Jun 18. No abstract available.

PMID:
31213436
3.

Evidence-Based Integrated Analysis of Environmental Hazards in Southern Bolivia.

Cantini F, Castelli G, Foderi C, Salazar Garcia A, López de Armentia T, Bresci E, Salbitano F.

Int J Environ Res Public Health. 2019 Jun 14;16(12). pii: E2107. doi: 10.3390/ijerph16122107.

4.

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice.

Cantini F, Niccoli L, Capone A, Petrone L, Goletti D.

Expert Opin Drug Saf. 2019 May;18(5):415-425. doi: 10.1080/14740338.2019.1612872. Epub 2019 May 8. Review.

PMID:
31066297
5.

Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases.

Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Massafra U, Baldi G, Navarra A, Scrivo R, Mastroianni C, Sauzullo I, Esposito C, Palmieri F, Cantini F, Goletti D.

J Infect. 2019 Jul;79(1):15-23. doi: 10.1016/j.jinf.2019.04.010. Epub 2019 Apr 11.

PMID:
30981891
6.

Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting.

Degli Esposti L, Perrone V, Sangiorgi D, Alessandrini D, Buda S, Cantini F, Mazzini E, Toma C, De Solda F.

Patient Prefer Adherence. 2019 Jan 22;13:187-194. doi: 10.2147/PPA.S178603. eCollection 2019.

7.

Impact of lipid binding on the tertiary structure and allergenic potential of Jug r 3, the non-specific lipid transfer protein from walnut.

Dubiela P, Del Conte R, Cantini F, Borowski T, Aina R, Radauer C, Bublin M, Hoffmann-Sommergruber K, Alessandri S.

Sci Rep. 2019 Feb 14;9(1):2007. doi: 10.1038/s41598-019-38563-1.

8.

Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement.

Marchesoni A, D'Angelo S, Anzidei M, Bortolotti R, Cantini F, Caramella D, Carotti M, Chimenti MS, Delle Sedie A, Egan CG, Fabbroni M, Frediani B, Fusaro E, Galeazzi M, Gallazzi MB, Gentileschi S, Gentili F, Gerli R, Gilio M, Iannone F, La Paglia E, Lubrano E, Macarini L, Olivieri I, Pellerito R, Ramonda R, Salvarani C, Scarano E, Scarpa R, Spaggiari L, Spanò A, Zawaideh JP, Mazzei MA; SHARE Study Group.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):575-584. Epub 2018 Nov 16.

PMID:
30557127
9.

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis.

Felice C, Leccese P, Scudeller L, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Olivieri I, Armuzzi A; Italian SpA-IBD Expert Panel Group.

Clin Exp Immunol. 2019 Apr;196(1):123-138. doi: 10.1111/cei.13246. Epub 2019 Jan 9.

PMID:
30554407
10.

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, Cassarà E, Kaloudi O, Cantini F.

Ther Clin Risk Manag. 2018 Oct 24;14:2097-2111. doi: 10.2147/TCRM.S175772. eCollection 2018.

11.

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

Cantini F, Benucci M.

Ann Rheum Dis. 2018 Nov 28. pii: annrheumdis-2018-214757. doi: 10.1136/annrheumdis-2018-214757. [Epub ahead of print] No abstract available.

PMID:
30487149
12.

Interaction of Half Oxa-/Half cis-Platin Complex with Human Superoxide Dismutase and Induced Reduction of Neurotoxicity.

Cantini F, Calderone V, Di Cesare Mannelli L, Korsak M, Gonnelli L, Francesconi O, Ghelardini C, Banci L, Nativi C.

ACS Med Chem Lett. 2018 Oct 1;9(11):1094-1098. doi: 10.1021/acsmedchemlett.8b00199. eCollection 2018 Nov 8.

PMID:
30429951
13.

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Cantini F, Benucci M.

Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018. Review.

14.

A synthetic peptide that prevents cAMP regulation in mammalian hyperpolarization-activated cyclic nucleotide-gated (HCN) channels.

Saponaro A, Cantini F, Porro A, Bucchi A, DiFrancesco D, Maione V, Donadoni C, Introini B, Mesirca P, Mangoni ME, Thiel G, Banci L, Santoro B, Moroni A.

Elife. 2018 Jun 20;7. pii: e35753. doi: 10.7554/eLife.35753.

15.

Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.

Goletti D, Petrone L, Ippolito G, Niccoli L, Nannini C, Cantini F.

Expert Rev Anti Infect Ther. 2018 Jun;16(6):501-512. doi: 10.1080/14787210.2018.1483238. Epub 2018 Jun 12. Review.

PMID:
29848120
16.

Epidemiology of Psoriasis and Psoriatic Arthritis in Italy-a Systematic Review.

Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F.

Curr Rheumatol Rep. 2018 May 30;20(7):43. doi: 10.1007/s11926-018-0753-1. Review.

PMID:
29846817
17.

Investigating the role of the human CIA2A-CIAO1 complex in the maturation of aconitase.

Maione V, Cantini F, Severi M, Banci L.

Biochim Biophys Acta Gen Subj. 2018 Sep;1862(9):1980-1987. doi: 10.1016/j.bbagen.2018.05.019. Epub 2018 May 26.

PMID:
29842905
18.

In search for a gold-standard procedure to count motor neurons in the spinal cord.

Ferrucci M, Lazzeri G, Flaibani M, Biagioni F, Cantini F, Madonna M, Bucci D, Limanaqi F, Soldani P, Fornai F.

Histol Histopathol. 2018 Oct;33(10):1021-1046. doi: 10.14670/HH-11-983. Epub 2018 Mar 14. Review.

PMID:
29537481
19.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J.

Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Review.

20.

Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke.

Cantini F, Benucci M.

Ann Rheum Dis. 2019 Apr;78(4):e25. doi: 10.1136/annrheumdis-2018-213044. Epub 2018 Feb 2. No abstract available.

PMID:
29420201
21.

Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O.

Eur J Rheumatol. 2017 Dec;4(4):288-290. doi: 10.5152/eurjrheum.2017.16112. Epub 2017 Oct 25.

22.

Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Cantini F, Benucci M.

Ann Rheum Dis. 2019 Apr;78(4):e23. doi: 10.1136/annrheumdis-2017-212820. Epub 2017 Dec 29. No abstract available.

PMID:
29288210
23.

Fragment-based approach to identify IDO1 inhibitor building blocks.

Coletti A, Camponeschi F, Albini E, Greco FA, Maione V, Custodi C, Ianni F, Grohmann U, Orabona C, Cantini F, Macchiarulo A.

Eur J Med Chem. 2017 Dec 1;141:169-177. doi: 10.1016/j.ejmech.2017.09.044. Epub 2017 Oct 3.

24.

Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts.

Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I; Italian SpA-IBD Expert Panel Group.

Dig Liver Dis. 2017 Dec;49(12):1298-1305. doi: 10.1016/j.dld.2017.06.004. Epub 2017 Jun 23. Review.

PMID:
28822731
25.

Enhanced Pru p 3 IgE-binding activity by selective free fatty acid-interaction.

Dubiela P, Aina R, Polak D, Geiselhart S, Humeniuk P, Bohle B, Alessandri S, Del Conte R, Cantini F, Borowski T, Bublin M, Hoffmann-Sommergruber K.

J Allergy Clin Immunol. 2017 Dec;140(6):1728-1731.e10. doi: 10.1016/j.jaci.2017.06.016. Epub 2017 Jul 14. No abstract available.

26.

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.

Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D.

Mediators Inflamm. 2017;2017:8909834. doi: 10.1155/2017/8909834. Epub 2017 Jun 1. Review.

27.

Direct Conversion of an Enzyme from Native-like to Amyloid-like Aggregates within Inclusion Bodies.

Elia F, Cantini F, Chiti F, Dobson CM, Bemporad F.

Biophys J. 2017 Jun 20;112(12):2540-2551. doi: 10.1016/j.bpj.2017.05.011.

28.

Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.

Semin Arthritis Rheum. 2017 Oct;47(2):183-192. doi: 10.1016/j.semarthrit.2017.03.008. Epub 2017 Mar 22. Review.

PMID:
28413099
29.

Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Rizzello F, Gionchetti P.

J Rheumatol. 2017 Sep;44(9):1341-1346. doi: 10.3899/jrheum.161518. Epub 2017 Apr 15.

PMID:
28412702
30.

Introduction.

Cantini F.

Expert Opin Drug Saf. 2016 Dec;15(sup1):1. No abstract available.

PMID:
27924647
31.

Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.

Matucci A, Cammelli D, Cantini F, Goletti D, Marino V, Milano GM, Scarpa R, Tocci G, Maggi E, Vultaggio A.

Expert Opin Drug Saf. 2016 Dec;15(sup1):3-10. Review.

PMID:
27924646
32.

Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.

Tocci G, Goletti D, Marino V, Matucci A, Milano GM, Cantini F, Scarpa R.

Expert Opin Drug Saf. 2016 Dec;15(sup1):55-61. Review.

PMID:
27924645
33.

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Bonovas S, Minozzi S, Lytras T, González-Lorenzo M, Pecoraro V, Colombo S, Polloni I, Moja L, Cinquini M, Marino V, Goletti D, Matucci A, Tocci G, Milano GM, Scarpa R, Cantini F.

Expert Opin Drug Saf. 2016 Dec;15(sup1):35-54. Review.

PMID:
27924644
34.

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, Gabrielli EM, Lonati AC, Moja L, Cinquini M, Marino V, Matucci A, Milano GM, Tocci G, Scarpa R, Goletti D, Cantini F.

Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. Review.

35.

A national survey on the management of psoriatic arthritis using the Delphi method.

Lubrano E, Cantini F, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Marchesoni A.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):214-220. Epub 2016 Aug 31.

PMID:
27607572
36.

Molecular Basis of Ligand-Dependent Regulation of NadR, the Transcriptional Repressor of Meningococcal Virulence Factor NadA.

Liguori A, Malito E, Lo Surdo P, Fagnocchi L, Cantini F, Haag AF, Brier S, Pizza M, Delany I, Bottomley MJ.

PLoS Pathog. 2016 Apr 22;12(4):e1005557. doi: 10.1371/journal.ppat.1005557. eCollection 2016 Apr.

37.

Structural characterization of zinc-bound Zmp1, a zinc-dependent metalloprotease secreted by Clostridium difficile.

Rubino JT, Martinelli M, Cantini F, Castagnetti A, Leuzzi R, Banci L, Scarselli M.

J Biol Inorg Chem. 2016 Apr;21(2):185-96. doi: 10.1007/s00775-015-1319-6. Epub 2015 Dec 28.

PMID:
26711661
38.

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3.

PMID:
26633622
39.

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the TAilored BIOlogic therapy (ITABIO).

Semin Arthritis Rheum. 2016 Apr;45(5):519-32. doi: 10.1016/j.semarthrit.2015.10.001. Epub 2015 Oct 22. Review.

PMID:
26607440
40.

Uveitis in Spondyloarthritis: An Overview.

Cantini F, Nannini C, Cassarà E, Kaloudi O, Niccoli L.

J Rheumatol Suppl. 2015 Nov;93:27-9. doi: 10.3899/jrheum.150630. Review.

PMID:
26523051
41.

Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.

Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, Scarpa R, Spadaro A.

Int J Rheum Dis. 2016 Aug;19(8):799-805. doi: 10.1111/1756-185X.12708. Epub 2015 Jul 14.

PMID:
26172207
42.

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.

Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, Olivieri I, Goldoni M, Vitale A, Silvestri E, Prisco D, Lapadula G, Galeazzi M, Iannone F, Cantarini L.

Clin Rheumatol. 2016 May;35(5):1281-6. doi: 10.1007/s10067-015-3004-0. Epub 2015 Jul 10.

PMID:
26156661
43.

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report.

Niccoli L, Cassarà E, Kaloudi O, Nannini C, Romagnoli M, Cantini F.

BMC Musculoskelet Disord. 2015 Jun 14;16:146. doi: 10.1186/s12891-015-0602-6.

44.

Measuring psoriatic disease in clinical practice. An expert opinion position paper.

Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I, Scarpa R, Spadaro A, Atzeni F, Narcisi A, Ricceri F, Sarzi-Puttini P.

Autoimmun Rev. 2015 Oct;14(10):864-74. doi: 10.1016/j.autrev.2015.05.010. Epub 2015 May 27. Review. Erratum in: Autoimmun Rev. 2016 Jan;15(1):112.

PMID:
26025585
45.

Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein.

Rippa V, Santini L, Lo Surdo P, Cantini F, Veggi D, Gentile MA, Grassi E, Iannello G, Brunelli B, Ferlicca F, Palmieri E, Pallaoro M, Aricò B, Banci L, Pizza M, Scarselli M.

Clin Vaccine Immunol. 2015 Jul;22(7):769-77. doi: 10.1128/CVI.00794-14. Epub 2015 May 6.

46.

Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.

Cantini F, Nannini C, Niccoli L, Iannone F, Delogu G, Garlaschi G, Sanduzzi A, Matucci A, Prignano F, Conversano M, Goletti D; SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy).

Autoimmun Rev. 2015 Jun;14(6):503-9. doi: 10.1016/j.autrev.2015.01.011. Epub 2015 Jan 21. Review.

PMID:
25617816
47.

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.

van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ.

Rheumatology (Oxford). 2015 Jul;54(7):1210-9. doi: 10.1093/rheumatology/keu438. Epub 2014 Dec 25.

48.

Infliximab monotherapy for neuro-Behçet's disease: a case report.

Di Filippo M, Di Gregorio M, Nannini C, Gaetani L, Gallina C, Floridi P, Sarchielli P, Calabresi P, Cantini F.

J Neurol Sci. 2014 Dec 15;347(1-2):389-90. doi: 10.1016/j.jns.2014.09.052. Epub 2014 Oct 7. No abstract available.

PMID:
25456463
49.

In-cell NMR reveals potential precursor of toxic species from SOD1 fALS mutants.

Luchinat E, Barbieri L, Rubino JT, Kozyreva T, Cantini F, Banci L.

Nat Commun. 2014 Nov 27;5:5502. doi: 10.1038/ncomms6502.

PMID:
25429517
50.

Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study.

Giacomelli R, Gorla R, Trotta F, Tirri R, Grassi W, Bazzichi L, Galeazzi M, Matucci-Cerinic M, Scarpa R, Cantini F, Gerli R, Lapadula G, Sinigaglia L, Ferraccioli G, Olivieri I, Ruscitti P, Sarzi-Puttini P.

Rheumatology (Oxford). 2015 May;54(5):792-7. doi: 10.1093/rheumatology/keu398. Epub 2014 Oct 6.

Supplemental Content

Loading ...
Support Center